Targeting Pim kinases in hematological cancers: molecular and clinical review

M Bellon, C Nicot - Molecular Cancer, 2023 - Springer
Decades of research has recognized a solid role for Pim kinases in lymphoproliferative
disorders. Often up-regulated following JAK/STAT and tyrosine kinase receptor signaling …

SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities

A Andrades, P Peinado, JC Alvarez-Perez… - Molecular cancer, 2023 - Springer
Hematological malignancies are a highly heterogeneous group of diseases with varied
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

WH Wilson, GW Wright, B Hodkinson… - Cancer cell, 2021 - cell.com
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis

D Barisic, CR Chin, C Meydan, M Teater, I Tsialta… - Cancer cell, 2024 - cell.com
ARID1A, a subunit of the canonical BAF nucleosome remodeling complex, is commonly
mutated in lymphomas. We show that ARID1A orchestrates B cell fate during the germinal …

Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression

G Han, Q Deng, ML Marques-Piubelli, E Dai… - Blood cancer …, 2022 - AACR
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that
is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to …

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

HJJ Cherng, R Sun, B Sugg, R Irwin… - Blood, The Journal …, 2022 - ashpublications.org
Patients with relapsed or refractory large B-cell lymphomas (rrLBCL) can achieve long-term
remission after CD19 chimeric antigen receptor T-cell therapy (CART19). However, more …

BTG1 mutation yields supercompetitive B cells primed for malignant transformation

C Mlynarczyk, M Teater, J Pae, CR Chin, L Wang… - Science, 2023 - science.org
Multicellular life requires altruistic cooperation between cells. The adaptive immune system
is a notable exception, wherein germinal center B cells compete vigorously for limiting …

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

Q Deng, P Lakra, P Gou, H Yang, C Meydan, M Teater… - Cancer cell, 2024 - cell.com
SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM
associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive …

CD24 is a potential immunotherapeutic target for mantle cell lymphoma

JÁ Freile, N Ustyanovska Avtenyuk, MG Corrales… - Biomedicines, 2022 - mdpi.com
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in
carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 …

[HTML][HTML] Artificial intelligence predicted overall survival and classified mature B-cell neoplasms based on immuno-oncology and immune checkpoint panels

J Carreras, G Roncador, R Hamoudi - Cancers, 2022 - mdpi.com
Simple Summary Artificial intelligence (AI) is a field that combines computer science with
robust datasets to solve problems. AI in medicine uses machine learning and deep learning …